ARTICLE | Company News
CMIC Co. Ltd., Dyax sales and marketing update
October 4, 2010 7:00 AM UTC
Dyax granted CRO CMIC exclusive rights in Japan to develop and commercialize Dyax's ecallantide ( DX-88) to treat hereditary angioedema (HAE) and other angioedema indications. Dyax markets the subcuta...